Wang-Da Liu, Po-Hao Feng, Chien-Yu Cheng, Chun-Liang Chou, Chih-Hsin Lee, Min-Chi Lu, Po-Yu Liu, Mei-Hui Lee, Chun-Hsing Liao, Mei-Chuan Chen, Cheng-Pin Chen, Shang-Fu Hsu, Yu-Tien Tzeng, Yi-Chun Lin, Tsong-Yih Ou, Albert Qin, Chan-Yen Tsai, Weichung Joe Shih, Kang-Yun Lee, Wang-Huei Sheng
INTRODUCTION: Ropeginterferon alfa-2b is a novel mono-pegylated proline-interferon. This clinical study aimed to evaluate its antiviral efficacy of ropeginterferon alfa-2b against SARS-CoV-2 infection. METHODS: This is a multicenter, randomized, open-label study. Adult patients with confirmed SARS-CoV-2 infection with initial cycle threshold (Ct) value < 30 and symptom onset within 4 days were enrolled. Eligible patients were randomized in a 2:1 ratio to receive a single 250-µg dose of ropeginterferon alfa-2b subcutaneously plus standard of care (SOC) or to receive SOC alone...
May 21, 2024: Infectious Diseases and Therapy